tbuckley/cabot-search huggingface dataset:
FRI0717-HPR A COMPARISON OF THE EFFECTIVENESS OF CORE STABILIZATION EXERCISE AND COMBINED EXERCISE ON PAIN, FATIGUE, SLEEP PROBLEM AND HEALTH STATUS IN WOMEN WITH FIBROMYALGIA
Authors: Oguzhan Mete, Seyda Toprak Celenay, Bahar Anaforoglu Kulunkoglu
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Fibromyalgia (FM) is a syndrome characterized mainly by chronic widespread pain, fatigue, sleep disorders and decrease in health status. Exercise, one of the non-pharmacological approach, has favorable effects on clinic findings in FM, but studies investigating which types of the exercise are more effective in FM are limited. <h3>Objectives</h3> This study aimed to compare the effectiveness of core stabilization exercise (CSE) and combined exercise (CE) on pain, fatigue, sleep problem and health status in women with FM. <h3>Methods</h3> A total of 34 women with FM were included, allocated into the CSE (n:18, age: 43.05±9.23 years, body mass index (BMI): 27.25±5.23 kg/m<sup>2</sup>) and the CE (n:16, age: 38.43±9.55 years, BMI: 25.62±3.68 kg/m<sup>2</sup>) groups. Both the CSE and the CE programs were carried out 2 days a week for 6 weeks under the supervision of a physiotherapist. Pain, fatigue and sleep problems with Visual Analog Scale and health status with Fibromyalgia Impact Questionnaire were evaluated at baseline and after 6-weeks program. <h3>Results</h3> Physical characteristics of the groups were similar (p<sub>age</sub>=0.162, p<sub>bmi</sub>=0.313). After the program, it was found that pain (p=0.001; p=0.014), fatigue (p=0,002; p=0.011), and sleep problem (p=0.007; p=0.039) decreased, health status (p=0.001; p=0.001) improved in both the CE and the CSE groups, respectively. Moreover, sleep problem decreased in the CE group in comparison to the CSE group (p=0.038); but pain (p=0.240), fatigue (p=0.178), and health status (p=0.098) did not differ between groups. <h3>Conclusion</h3> In this study, it was observed that both the CSE and the CE programs were effective in decreasing pain, fatigue, sleep problem and improving health status of women with FM. In addition, the study suggested that the CE was superior in decreasing sleep problem in comparison to the CSE in women with FM. In clinics, both the CSE and the CE programs may be preferred to improve the symptoms of FM; however, the CE should be taken into account for the sleep problems in FM. <h3>References</h3> [1] Busch, A. J., Webber, S. C., Brachaniec, M., Bidonde, J., Dal Bello-Haas, V., Danyliw, A. D.,. .. &amp; Schachter, C. L. (2011). Exercise therapy for fibromyalgia. Current pain and headache reports, 15(5), 358. [2] Sosa-Reina, M. D., Nunez-Nagy, S., Gallego-Izquierdo, T., Pecos-Martín, D., Monserrat, J., &amp; Álvarez-Mon, M. (2017). Effectiveness of therapeutic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomized clinical trials. BioMed research international, 2017. <h3>Disclosure of Interests</h3> None declared
AB0664 REYNOLDS SYNDROME: ABOUT 7 CASES
Authors: KCHIR hela, Ons Gharbi, Dhouha Cherif, Dhilel Issaoui, Faten Limaiem, Dhia Kaffel, Nadia Maamouri
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Reynolds syndrome is a rare condition defined by the association of primary biliary cholangitis (PBC) with CREST syndrome. The frequency of scleroderma during PBC varies between 3 and 17%. The diagnosis is most often done during systematic search for autoimmune diseases associated with CBP. <h3>Objectives:</h3> To determine the epidemiological, clinical, paraclinical and evolutionary features of Reynolds syndrome <h3>Methods:</h3> We report 7 cases of Reynolds syndrome collected in the our department between 1996 and 2014 <h3>Results:</h3> There were 7 middle-aged women with an average age of 49.2 years (32-61 years old). The diagnosis of CREST syndrome with anti centromeric positive antibodies was retained in 6 cases. Extensive trunk sclerosis associated with diffuse sclerodacty and anti centromeric antibodies was noted in 1 case. An isolated acrosyndrome was noted in 1 case. The hepatic assessment found non icteric cholestasis in 6 patients. Anti-mitochondrial antibodies type M2 were positive in 6 cases. Liver biopsy showed histologic lesions consistent with primary biliary cholangitis PBC in 5 cases. Sjörgen's syndrome was confirmed histologically in 1 case. Autoimmune diseases (rheumatoid arthritis and lymphocytic thyroiditis) were associated with Reynolds Syndrome in 2 cases. The treatment consisted of ursodeoxycholic acid alone (N = 4), or combined with D-penicillamine (N = 1), azathioprine-associated prednisone (N = 1) or a calcium channel blocker alone (N = 1). The evolution was favorable in 2 cases. In the other 3 patients, worsening of cholestasis and complications such as oedemato-ascitic decompensation and gastrointestinal haemorrhage were noted during the course of the study. One patient died of cataclysmic gastrointestinal bleeding by rupture of oesophageal varices. <h3>Conclusion:</h3> Reynolds syndrome is a rare entity that should be discussed in the presence of liver function disturbances in patients with CREST syndrome. Conversely, the CREST syndrome should be referred to and sought systematically in case of PBC. <h3>Disclosure of interests:</h3> None declared
The Demise of Vitamin D for Cardiovascular Prevention
Authors: Arshed A. Quyyumi, Ibhar Al Mheid
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Excellent Outcome of Elderly Patients with Favourable-Prognosis DLBCL Treated with 4 Cycles CHOP/Chlip-14 Plus 8 Applications of Rituximab and a PET-Based Intensification Strategy That Includes Involved-Site Radiotherapy (IS-RT): Results of the First 120 Patients of the OPTIMAL>60 Trial of the Dshnhl
Authors: Michael Pfreundschuh, Niels Murawski, Konstantinos Christofyllakis, Bettina Altmann, Marita Ziepert, Mathias Haenel, Andreas Viardot, Andreas Neubauer, Gerhard Held, Lorenz Truemper, Christian Schmidt, Lothar Kanz, Kai Huebel, Norbert Schmitz, Tobias Heintges, Heinz Kirchen, Günther Schneider, Christian Ruebe, Christian Berdel, Dirk Hellwig, Jirka Grosse, Viola Poeschel
Journal: Blood (2017)
The puzzle of lactational bone physiology: osteocytes masquerade as osteoclasts and osteoblasts
Authors: Brittany A. Ryan, Christopher S. Kovacs
Journal: Journal of Clinical Investigation (2019)

Lactation is a unique period in which the maternal skeleton acts as a storehouse to provide substantial calcium to milk. Women who exclusively breastfeed lose an average of 210 mg of calcium per day, which doubles or triples with twins and triplets. Data from rodent and clinical studies are consistent with skeletal calcium being released to provide much of the calcium needed for milk production. This is programmed to occur independently of dietary calcium intake or intestinal calcium absorption, which remains at the prepregnant rate in breastfeeding women. After weaning, the skeleton is restored to its prior mineralization and strength, but the factors that regulate this remain to be elucidated.
The Cardiometabolic Risk Profile of Young Adults With Diabetes in the U.S.
Authors: Sharon H. Saydah, Karen R. Siegel, Giuseppina Imperatore, Carla Mercado, Edward W. Gregg
Journal: Diabetes Care (2019)

OBJECTIVE We examined young adults with and young adults without diabetes by using demographic data and cardiometabolic risk profiles and compared the risk profiles of younger versus older (aged ≥45 years) adults with diabetes. RESEARCH DESIGN AND METHODS Data were obtained from the National Health and Nutrition Examination Survey (NHANES) 2007–2016. Diabetes was defined by self-report of health care provider diagnosis or by A1C levels of 6.5% or higher among those without a self-reported diagnosis. The cardiometabolic risk profile included adiposity, blood pressure, serum lipids, healthy eating, physical activity (PA), and exposure to tobacco smoke. Adjusted difference in difference was calculated as the difference among younger adults with and younger adults without diabetes minus the difference among older adults with and older adults without diabetes. RESULTS Adults with diabetes in both age-groups had higher levels of adiposity, hypertension, and cholesterol and lower levels of healthy eating and leisure-time PA. However, the differences in high cholesterol and adiposity by diabetes status were greater among young adults compared with older adults after adjustment for demographics and health insurance status. Elevated lipids were 9.6 percentage points higher (95% CI 4.6, 14.5) and obesity was 37.3 percentage points higher (95% CI 31.8, 42.7) among young adults with diabetes compared with those without diabetes than among older adults with diabetes compared with those without diabetes. CONCLUSIONS Young adults with diabetes have high rates of cardiometabolic risk factors, which can lead to an increased disease prevalence and mortality rate among these individuals as they age.
Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire
Authors: Sabrina Pollastro, Paul L Klarenbeek, Marieke E Doorenspleet, Barbera D C van Schaik, Rebecca E E Esveldt, Rogier M Thurlings, Maria J H Boumans, Danielle M Gerlag, Paul P Tak, Koen Vos, Frank Baas, Antoine H C van Kampen, Niek de Vries
Journal: Annals of the Rheumatic Diseases (2019)

Objective To gain more insight into the dynamics of lymphocyte depletion and develop new predictors of clinical response to rituximab in rheumatoid arthritis (RA). Methods RNA-based next-generation sequencing was used to analyse the B cell receptor (BCR) repertoire in peripheral blood and synovial tissue samples collected from 24 seropositive patients with RA treated with rituximab. Clonal expansion, mutation load and clonal overlap were assessed in samples collected before, at week 4 and at week 16 or 24 after treatment and correlated to the patients’ clinical response. Results After 4 weeks of rituximab-induced B cell depletion, the peripheral blood BCR repertoire of treated patients consisted of fewer, more dominant and more mutated BCR clones. No significant changes in the synovial tissue BCR repertoire were detected until week 16 post-treatment, when a reduced clonal overlap with baseline and an increased mutation load were observed. In patients who were non-responders at month 3 (n=5) using the European League Against Rheumatism response criteria, peripheral blood samples taken at week 4 after rituximab treatment showed more dominant clones compared with moderate responders (n=9) (median (IQR): 36 (27–52) vs 18 (16–26); p&lt;0.01) and more clonal overlap with the baseline (median (IQR): 5% (2%–20%) vs 0% (0%–0%); p≤0.01). Conclusion Significant changes in BCR clonality are observed in peripheral blood of patients 4 weeks after rituximab treatment, while changes in synovial tissue were observed at later time points. Incomplete depletion of the dominant baseline peripheral blood BCR repertoire in the first month of treatment might predict clinical non-response at 3 months.
PB1757 MORPHOLOGICAL CHARACTERISTICS, CYTOGENETIC PROFILEAND TREATMENT OUTCOME OF AML1‐ETO POSITIVE ACUTE MYELOID LEUKEMIA; INDIAN PERSPECTIVE.
Authors: None S., R. Gupta, A. Gupta, A. Garg, K. Rehman, S. Nityanand
Journal: HemaSphere (2019)

Background: Acute myeloid leukemia (AML) is characterized by the proliferation of leukemic myeloid blasts bearing granules and/or Auer rods. Besides acute promyelocytic leukemia, the myeloid blasts in other subtypes of AML have a non‐descript morphology. Aims: The aim of this analysis was to determine the morphological features of t (8;21) positive AML and define a score for predicting positivity for this fusion protein in AML. Methods: A retrospective analysis of all the cases of AML diagnosed over a period of five years (2013‐2017) at our centre was performed. The clinical and laboratory data of the patients was collected from the patient medical records. The bone marrow aspirate smears were reviewed to define the specific features of t (8;21) positive AML; dyspoiesis in maturing granulocytes, long thin Auer rods, eosinophilia, cytoplasmic vacuoles and presence of Auer rods in maturing myeloid cells. Results: A total of 68 cases of t (8;21) positive AML were diagnosed during the study period, with a median age of 19.5 years (range 5‐75 years) with a M:F of 1.7:1. Only twenty percent (14/68) patients belonged to the paediatric age‐group (≤14 years). Granulocytic sarcoma was observed in 10.2% patients at presentation. Morphologically, in accordance to the FAB classification there were 56 AML‐M2, 5 AML‐M1 and 7 AML‐M4 subtypes. Thirteen cases (n = 68) exhibited less than 20% blast in the bone marrow. Characteristic morphological features included presence of dyspoiesis (71%), slender long Auer rods (48%), eosinophilia (19%) cytoplasmic vacuoles in the golgi zone of blasts and maturing myeloid cells (48%). Mast cells, and Auer rods in maturing granulocytic series of cells were seen in a very small fraction of patients, 11% and 3% respectively. 29/68 patients opting for treatment were managed as per the 3+7 protocol. Seventy percent (21/30) achieved CR; there were 5 induction and 8 post induction deaths. With a median follow‐up of 27 months, (range 4‐51 months), the overall survival is 40%. Eleven patients relapsed with a median interval of 7 months, twelve patients‐maintained CR. Summary/Conclusion: Since this sub‐group of AML is believed to be a harbinger of good prognosis, recognition of the distinct morphological features of AML1‐ETO AML is essential; it will facilitate a screening for this genetic abnormality. There was no prognostic correlation with any laboratory parameter, however, presence of granulocytic sarcoma in these patients portends a poor prognosis.
Abstract P100: Heritability of Atrial Fibrillation
Authors: Lu-Chen Weng, Seung Hoan Choi, Derek Klarin, Po-Ru Loh, Mark Chaffin, Carolina Roselli, Olivia Hulme, J. Gustav Smith, Sekar Kathiresan, Kathryn Lunetta, Josée Dupuis, Chris Newton-Cheh, Emelia J Benjamin, Patrick T Ellinor, Steven A Lubitz
Journal: Circulation (2017)

Background: Atrial fibrillation (AF) is a common and heritable arrhythmia associated with substantial morbidity. Previous reports have implicated over 30 genes and 16 loci in the pathogenesis of AF, but the genetic architecture of the arrhythmia has not been systematically characterized. Methods: We assessed AF heritability in 120,286 unrelated individuals of European ancestry (2,981 with AF) from the population-based UK Biobank. We ascertained AF based on self-reported disease history and/or billing codes from medical record data. To validate the phenotype definition, we examined genetic associations with AF for variants at known susceptibility loci reported in prior independent genome-wide association studies. We then estimated the proportion of AF variance explained by additive genetic variation (heritability) using a variance components method (BOLT-REML) based on ~800,000 independent high quality imputed variants with minor allele frequencies (MAF) ≥ 1%. We further evaluated the heritability of AF by sex, allele frequency, and established AF loci from association studies (+/- 500 kb of a top associated variant). All analyses were adjusted for baseline age, sex, array, and 15 principal components of ancestry. Results: The average age was higher in AF cases than in referents (62.3 years vs. 56.8 years), and more AF cases were male (69% vs. 47%). We observed expected associations between genetic variation and AF, validating our AF definition. The heritability of AF was 22.3% (95% confidence interval [CI] 15.8%-28.8%), and no substantive difference was observed between males and females. We observed that the AF variance was mainly explained by common variants with MAF ≥ 5% (20.6%, 95%CI 15.2%-25.9%) rather than low-frequency variants with MAF between 1%-&lt;5% (0%, 95%CI 0.0%-0.06%). Only 4.7% (95%CI 3.7%-5.7%) of AF variance was explained by known AF susceptibility loci. Conclusions: Using a population-based sample of European ancestry, we observed that a substantial proportion of variance in AF risk is attributable to additive genetic variation. AF variance is predominantly accounted for by common variants. Only a small proportion of AF variance is attributable to known AF loci. Our findings suggest that further genetic discovery, with an emphasis on common variation, is warranted to understand the causal genetic basis of AF.
PF549 AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATE TO R‐IPSS SCORE BUT NOT TO OVERALL SURVIVAL OR LEUKEMIC EVOLUTION IN MYELODYSPLASTIC SYNDROMES
Authors: T. Brunet, F. Roy‐Peaud, C. Landron, M.P. Gallego‐Hernanz, E. Cayssials, M. Puyade, J.M. Torregrosa‐Díaz
Journal: HemaSphere (2019)

Background: Myelodysplastic syndromes (MDS) are clonal hemopathies with a relatively heterogeneous spectrum of presentation and a variable risk of transformation into acute myeloid leukemia (AML). Autoimmune diseases (AID) are present in 10 to 30% of MDS, with uncertain prognostic significance in this context. To date, no MDS‐related factor has been clearly identified as a predictor for the occurrence of AIDs. Aims: To study the association between MDS characteristics and the occurrence of an AID and its impact on overall survival and leukemia‐free survival. Methods: We retrospectively collected data from primary MDS adult patients followed‐up at the University Hospital of Poitiers between January 2010 and December 2017. Immunosuppressive therapy secondary‐MDS were excluded. The date of onset and type of AID as established by the standard criteria were collected. Steroid dependence was defined as a prednisone equivalent amount &gt; 10 mg/day during at least 3 months. Simultaneous diagnosis of MDS and AID were considered if established in a 3‐months interval from the MDS one. Baseline characteristics at diagnosis of the MDS were registered and compared between those with and without AIDs. Results: AIDs were identified in 44 of 179 MDS patients (24.6%). MDS‐AID patients were more frequently male (29/44, p &lt; 0.05). AIDs occurred before MDS in 63.6% of cases. Associated AIDs were: systemic vasculitis (23%), inflammatory rheumatism (18%), neutrophilic dermatosis (12.5%), connective tissue diseases (12.5%) and autoimmune cytopenia (11%). At the time of AID diagnosis, 48% of patients had general signs, 37.5% had cutaneous and/or joint signs. AID was steroid‐dependent in 39% of cases (9/23). No association between AID and MDS subtypes was observed. A significant linear tendency was found between the R‐IPSS and the presence of AID (p = 0.02): that is, the lower the IPSS‐R score, the higher the risk of association with AID. The presence of AID did not affect survival or progression to acute leukemia. Summary/Conclusion: The association of MDS to AIDs is frequent and of clinical heterogeneous expression. It occurs mainly in low‐risk MDS and does not seem to impact overall survival, that seems logical. The pathogenic mechanisms are complex and remain still completely unknown, but the hypothesis of a common pathogenic pathway seems strongly supported. The association MDS‐AID does not seem to impact overall survival in our cohort and occurs mainly in low‐risk MDS with a significant linear augmentation of the risk by the creasing categories of R‐IPSS. That raises the question of the role of different physio‐pathological processes underlying low‐risk and high‐risk MDS in the predisposition of AIDs. Larger prospective ongoing studies will better clarify our results.
Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer’s disease
Authors: Ivan Koychev, Jennifer Lawson, Tharani Chessell, Clare Mackay, Roger Gunn, Barbara Sahakian, James B Rowe, Alan J Thomas, Lynn Rochester, Dennis Chan, Brian Tom, Paresh Malhotra, Clive Ballard, Iain Chessell, Craig W Ritchie, Vanessa Raymont, Iracema Leroi, Imre Lengyel, Matt Murray, David L Thomas, John Gallacher, Simon Lovestone
Journal: BMJ (2019)

Introduction  Recent failures of potential novel therapeutics for Alzheimer’s disease (AD) have prompted a drive towards clinical studies in prodromal or preclinical states. However, carrying out clinical trials in early disease stages is extremely challenging—a key reason being the unfeasibility of using classical outcome measures of dementia trials (eg, conversion to dementia) and the lack of validated surrogate measures so early in the disease process. The Deep and Frequent Phenotyping (DFP) study aims to resolve this issue by identifying a set of markers acting as indicators of disease progression in the prodromal phase of disease that could be used as indicative outcome measures in proof-of-concept trials.  Methods and analysis  The DFP study is a repeated measures observational study where participants will be recruited through existing parent cohorts, research interested lists/databases, advertisements and memory clinics. Repeated measures of both established (cognition, positron emission tomography (PET) imaging or cerebrospinal fluid (CSF) markers of pathology, structural MRI markers of neurodegeneration) and experimental modalities (functional MRI, magnetoencephalography and/or electroencephalography, gait measurement, ophthalmological and continuous smartphone-based cognitive and other assessments together with experimental CSF, blood, tear and saliva biomarkers) will be performed. We will be recruiting male and female participants aged >60 years with prodromal AD, defined as absence of dementia but with evidence of cognitive impairment together with AD pathology as assessed using PET imaging or CSF biomarkers. Control participants without evidence of AD pathology will be included at a 1:4 ratio.  Ethics and dissemination  The study gained favourable ethical opinion from the South Central—Oxford B NHS Research Ethics Committee (REC reference 17/SC/0315; approved on 18 August 2017; amendment 13 February 2018). Data will be shared with the scientific community no more than 1 year following completion of study and data assembly.